Yunchao Wang - Search Results

Year	Number of Results
2013	1
2014	1
2015	4
2016	5
2017	2
2018	8
2019	7
2020	7
2021	7
2022	23
2023	29
2024	29
2025	16
2026	24

1

Unraveling the protein post-translational modification landscape: Neuroinflammation and neuronal death after stroke.

Tao J, Li J, Fan X, Jiang C, Wang Y, Qin M, Nikfard Z, Nikfard F, Wang Y, Zhao T, Xing N, Zille M, Wang J, Zhang J, Chen X, Wang J. Tao J, et al. Among authors: wang y. Ageing Res Rev. 2024 Nov;101:102489. doi: 10.1016/j.arr.2024.102489. Epub 2024 Sep 12. Ageing Res Rev. 2024. PMID: 39277050 Review.

2

Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.

Mao J, Wang D, Long J, Yang X, Lin J, Song Y, Xie F, Xun Z, Wang Y, Wang Y, Li Y, Sun H, Xue J, Song Y, Zuo B, Zhang J, Bian J, Zhang T, Yang X, Zhang L, Sang X, Zhao H. Mao J, et al. Among authors: wang y. J Immunother Cancer. 2021 Dec;9(12):e003334. doi: 10.1136/jitc-2021-003334. J Immunother Cancer. 2021. PMID: 34873013 Free PMC article.

3

Dynamic urinary proteomics integrates single-cell and spatial transcriptomics to reveal tumour microenvironment and predict immunotherapy response in biliary tract cancer.

Wang S, Guo Z, Sun B, Liu K, Chao J, Xun Z, Wang Y, Xu Z, Huang Z, Wang H, Tan Y, Zhang N, Piao M, Zhang L, Li C, Li S, Li J, Sun H, Qi F, Wang A, Yang X, Zhu C, Wang H, Sun W, Zhao H. Wang S, et al. Among authors: wang y. Gut. 2026 Jun 9;75(7):1411-1424. doi: 10.1136/gutjnl-2025-335513. Gut. 2026. PMID: 41151791 Free PMC article.

4

GGC repeat expansion in NOTCH2NLC induces dysfunction in ribosome biogenesis and translation.

Fan Y, Li MJ, Yang J, Li SJ, Hao XY, Li JD, Wang YC, Tang MB, Zhang C, Shi JJ, Ma DR, Guo MN, Liu F, Shen S, Yao DB, Zuo CY, Mao CY, Hu ZW, Zhang S, Yang ZH, Guo GY, Yang JH, Xia ZP, Xu YM, Shi CH. Fan Y, et al. Brain. 2023 Aug 1;146(8):3373-3391. doi: 10.1093/brain/awad058. Brain. 2023. PMID: 36825461 Free article.

5

Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma.

Yang X, Lian B, Zhang N, Long J, Li Y, Xue J, Chen X, Wang Y, Wang Y, Xun Z, Piao M, Zhu C, Wang S, Sun H, Song Z, Lu L, Dong X, Wang A, Liu W, Pan J, Hou X, Guan M, Huo L, Shi J, Zhang H, Zhou J, Lu Z, Mao Y, Sang X, Wu L, Yang X, Wang K, Zhao H. Yang X, et al. Among authors: wang y. BMC Med. 2024 Jan 29;22(1):42. doi: 10.1186/s12916-024-03257-7. BMC Med. 2024. PMID: 38281914 Free PMC article.

6

Radiation Therapy With Combination Therapy of Immune Checkpoint Inhibitors and Antiangiogenic Therapy for Hepatocellular Carcinoma.

Ning C, Zhang X, Wang Y, Yang X, Yang X, Chao J, Xun Z, Xue J, Wang Y, Sun H, Li Y, Zhang N, Zhu C, Hou X, Sang X, Zhao H. Ning C, et al. Among authors: wang y. Int J Radiat Oncol Biol Phys. 2024 Apr 1;118(5):1461-1471. doi: 10.1016/j.ijrobp.2023.07.001. Epub 2023 Jul 9. Int J Radiat Oncol Biol Phys. 2024. PMID: 37433375 Free article.

7

Mechanistic insights into bisphenol A - Induced liver fibrosis: Evidence of PPARγ downregulation and AKT1/FN1 signaling from multi-level analysis.

He QJ, Yin YC, Xu YY, Tan X, Wang YC, Zhang W. He QJ, et al. Ecotoxicol Environ Saf. 2025 Sep 15;303:119068. doi: 10.1016/j.ecoenv.2025.119068. Epub 2025 Sep 16. Ecotoxicol Environ Saf. 2025. PMID: 40961596 Free article.

8

Novel cellular therapies for hepatobiliary malignancies.

Xue JN, Wang YY, Wang YC, Zhang N, Zhang LH, Lu ZH, Zhao LJ, Zhao HT. Xue JN, et al. Hepatobiliary Pancreat Dis Int. 2022 Oct;21(5):450-454. doi: 10.1016/j.hbpd.2022.08.014. Epub 2022 Sep 6. Hepatobiliary Pancreat Dis Int. 2022. PMID: 36100543 Review.

9

Gut microbiota and metabolite signatures predict severe immune-related adverse events in advanced hepatobiliary cancers.

Zhu C, Zhang D, Wang Y, Zhang C, Wang S, Xue J, Lan Z, Xun Z, Zhang L, Chao J, Liang Y, Xue W, Pu Z, Zhu T, Ning C, Sang X, Wang H, Jiang X, Yang X, Zhao H. Zhu C, et al. Among authors: wang y. J Adv Res. 2026 May;83:775-787. doi: 10.1016/j.jare.2025.08.016. Epub 2025 Aug 12. J Adv Res. 2026. PMID: 40812586 Free PMC article.

10

Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma.

Zhang N, Yang X, Piao M, Xun Z, Wang Y, Ning C, Zhang X, Zhang L, Wang Y, Wang S, Chao J, Lu Z, Yang X, Wang H, Zhao H. Zhang N, et al. Among authors: wang y. Biomark Res. 2024 Feb 14;12(1):26. doi: 10.1186/s40364-023-00535-z. Biomark Res. 2024. PMID: 38355603 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

149 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

149 results

Results by year